12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cialis: Phase III data

A double-blind, international Phase III trial in 511 men aged 45 years and older with signs and symptoms of BPH showed that once-daily 5 mg Cialis met the primary endpoint of significantly improving IPSS scores from baseline to week 12 vs. placebo (2.1 point greater reduction relative to placebo, p=0.001). The active control tamsulosin also met the endpoint vs. placebo (1.5 point greater reduction relative to placebo, p=0.023). On secondary endpoints, Cialis and tamsulosin...

Read the full 346 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >